BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25231113)

  • 21. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
    Alsayed Y; Ngo H; Runnels J; Leleu X; Singha UK; Pitsillides CM; Spencer JA; Kimlinger T; Ghobrial JM; Jia X; Lu G; Timm M; Kumar A; Côté D; Veilleux I; Hedin KE; Roodman GD; Witzig TE; Kung AL; Hideshima T; Anderson KC; Lin CP; Ghobrial IM
    Blood; 2007 Apr; 109(7):2708-17. PubMed ID: 17119115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.
    Kawaguchi A; Orba Y; Kimura T; Iha H; Ogata M; Tsuji T; Ainai A; Sata T; Okamoto T; Hall WW; Sawa H; Hasegawa H
    Blood; 2009 Oct; 114(14):2961-8. PubMed ID: 19657116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CC chemokine receptor 2 (CCR2) expression promotes diffuse large B-Cell lymphoma survival and invasion.
    Hu QQ; Wen ZF; Huang QT; Li Q; Zhai ZM; Li YL
    Lab Invest; 2022 Dec; 102(12):1377-1388. PubMed ID: 35851856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
    Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
    Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.
    Zhang Y; You X; Liu H; Xu M; Dang Q; Yang L; Huang J; Shi W
    Ann Hematol; 2017 Sep; 96(9):1485-1491. PubMed ID: 28616658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
    Benedicto A; Romayor I; Arteta B
    Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
    Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
    Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival.
    Bian XW; Yang SX; Chen JH; Ping YF; Zhou XD; Wang QL; Jiang XF; Gong W; Xiao HL; Du LL; Chen ZQ; Zhao W; Shi JQ; Wang JM
    Neurosurgery; 2007 Sep; 61(3):570-8; discussion 578-9. PubMed ID: 17881971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
    Mao TL; Fan KF; Liu CL
    Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion.
    Heckmann D; Laufs S; Maier P; Zucknick M; Giordano FA; Veldwijk MR; Eckstein V; Wenz F; Zeller WJ; Fruehauf S; Allgayer H
    Onkologie; 2011; 34(10):502-8. PubMed ID: 21985848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Zhu WB; Zhao ZF; Zhou X
    J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
    Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
    Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
    Peng W; Wu J; Feng J
    Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
    Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
    Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of circulating CD34(+) cells with SDF-1alpha or anti-CXCR4 antibody enhances migration and NOD/SCID repopulating potential.
    Plett PA; Frankovitz SM; Wolber FM; Abonour R; Orschell-Traycoff CM
    Exp Hematol; 2002 Sep; 30(9):1061-9. PubMed ID: 12225798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma.
    Li YL; Shi ZH; Wang X; Gu KS; Zhai ZM
    Ann Hematol; 2019 Feb; 98(2):413-422. PubMed ID: 30374624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
    Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
    J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.
    Bosch R; Moreno MJ; Dieguez-Gonzalez R; Céspedes MV; Gallardo A; Trias M; Grañena A; Sierra J; Casanova I; Mangues R
    Haematologica; 2013 Aug; 98(8):1242-9. PubMed ID: 23716554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.
    Xu PP; Sun YF; Fang Y; Song Q; Yan ZX; Chen Y; Jiang XF; Fei XC; Zhao Y; Leboeuf C; Li B; Wang CF; Janin A; Wang L; Zhao WL
    Sci Rep; 2017 Aug; 7(1):7433. PubMed ID: 28785100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.